Literature DB >> 10871712

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.

M E Liechti1, F X Vollenweider.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") releases serotonin and dopamine. The role for dopamine in mediating the effects of MDMA has not yet been examined in humans. We investigated the effect of pretreatment with the dopamine D(2) antagonist haloperidol (1.4 mg i.v.) on psychological and physiological responses to MDMA (1.5 mg/kg p.o.) in 14 healthy volunteers using a double-blind placebo-controlled within-subject design. Subjective peak effects were rated using standardised scales. The physiological effects measured were blood pressure, heart rate and body temperature. Side effects were assessed during the session, and after 1 and 3 days. Haloperidol attenuated MDMA-induced positive and mania-like mood but had no reducing effect on other subjective changes or on cardiovascular effects. Results are consistent with a partial dopaminergic mediation of the euphoriant effects of MDMA. In contrast, dopamine does not seem to contribute to the physiological effects of MDMA, indicating a role for serotonin and norepinephrine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871712     DOI: 10.1016/s0924-977x(00)00086-9

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  28 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

3.  Altered Insula Connectivity under MDMA.

Authors:  Ishan C Walpola; Timothy Nest; Leor Roseman; David Erritzoe; Amanda Feilding; David J Nutt; Robin L Carhart-Harris
Journal:  Neuropsychopharmacology       Date:  2017-02-14       Impact factor: 7.853

4.  The Basal Ganglia as a Substrate for the Multiple Actions of Amphetamines.

Authors:  Reka Natarajan; Bryan K Yamamoto
Journal:  Basal Ganglia       Date:  2011-07-01

Review 5.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

6.  The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Manuel Tancer; Chris-Ellyn Johanson
Journal:  Psychopharmacology (Berl)       Date:  2006-10-18       Impact factor: 4.530

7.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

8.  Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.

Authors:  N P Pedersen; W W Blessing
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 9.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

10.  Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.

Authors:  Susan Schenk; David Gittings; Malcolm Johnstone; Evangeline Daniela
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.